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Metabolic Profiling Predicts Response to
Anti–Tumor Necrosis Factor  Therapy in Patients With
Rheumatoid Arthritis
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Karim Raza,1 and Stephen P. Young3
Objective. Anti–tumor necrosis factor (anti-TNF)
therapies are highly effective in rheumatoid arthritis
(RA) and psoriatic arthritis (PsA), but a significant
number of patients exhibit only a partial or no thera-
peutic response. Inflammation alters local and systemic
metabolism, and TNF plays a role in this. We undertook
this study to determine if the patient’s metabolic finger-
print prior to therapy could predict responses to anti-
TNF agents.
Methods. Urine was collected from 16 RA patients
and 20 PsA patients before and during therapy with
infliximab or etanercept. Urine metabolic profiles were
assessed using nuclear magnetic resonance spectros-
copy. Discriminating metabolites were identified, and
the relationship between metabolic profiles and clinical
outcomes was assessed.
Results. Baseline urine metabolic profiles dis-
criminated between RA patients who did or did not have
a good response to anti-TNF therapy according to
European League Against Rheumatism criteria, with a
sensitivity of 88.9% and a specificity of 85.7%, with
several metabolites contributing (in particular hista-
mine, glutamine, xanthurenic acid, and ethanolamine).
There was a correlation between baseline metabolic
profiles and the magnitude of change in the Disease
Activity Score in 28 joints from baseline to 12 months in
RA patients (P  0.04). In both RA and PsA, urinary
metabolic profiles changed between baseline and 12
weeks of anti-TNF therapy. Within the responders,
urinary metabolite changes distinguished between etan-
ercept and infliximab treatment.
Conclusion. The clear relationship between urine
metabolic profiles of RA patients at baseline and their
response to anti-TNF therapy may allow development of
novel approaches to the optimization of therapy. Differ-
ences in metabolic profiles during treatment with inf-
liximab and etanercept in RA and PsA may reflect
distinct mechanisms of action.
The introduction of anti–tumor necrosis fac-
tor  (anti-TNF) treatment has revolutionized the
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management of rheumatoid arthritis (RA) (1–4). Sev-
eral agents are available within this class, but response
rates are imperfect; only 26–42% of patients achieve a
good European League Against Rheumatism (EULAR)
response (5) within 6 months (6–8). Given the high cost
of these therapies and implications for disease progres-
sion in nonresponders waiting 3–6 months for clinical
reassessment, the ability to predict treatment responses
at baseline is an important goal.
The etiology of RA is not fully understood but
involves both genetic and environmental factors. In
addition to synovitis there are widespread systemic
effects mediated by proinflammatory cytokines that af-
fect metabolism. Muscle wasting is a common feature of
RA and its extent is associated with RA disease activity
(9), but low body mass index is uncommon as fat mass is
preserved or even increased (10). The extent of the
metabolic changes and the types of metabolites seen
may therefore be good markers of cytokine-mediated
inflammatory processes in RA.
Several studies have used metabolomic analysis
in patients and animal models of inflammatory disease
(11–15). Given the integrated nature of systemic metab-
olism, the analysis of multiple metabolites may provide a
better understanding of the disease-associated changes.
Metabolomic analysis, based on nuclear magnetic reso-
nance (NMR) spectroscopy of biofluids, can be used to
identify a broad range of metabolites simultaneously.
Using this approach, the identification of several metab-
olites in cancer and cardiovascular disease has provided
insights into disease mechanisms and has highlighted
their potential as biomarkers of disease activity and
response to therapy (16–18).
Systemic changes in many low molecular weight
metabolites are reflected by their levels in urine, and,
indeed, metabolomic analysis of urine samples has been
used in inflammatory conditions such as inflammatory
bowel disease (IBD) (19–21), to successfully distinguish
different types of IBD, and to identify the presence of
ongoing intestinal inflammation. Metabolomic profiles
have also been shown to be altered during therapy (16).
Consequently, we sought to assess whether metabolomic
profiles in the urine may have a role in predicting
responses to TNF antagonists in patients with RA and
psoriatic arthritis (PsA).
PATIENTS AND METHODS
Patients. Patients were part of a multicenter study
(Glasgow Royal Infirmary [PsA patients only], Queen Eliza-
beth Hospital, Birmingham [PsA patients only], and Charing
Cross Hospital, London [RA patients only]) comparing re-
sponses to infliximab and etanercept. All patients were age
18 years. RA patients were required to fulfill the 1987 revised
classification criteria of the American College of Rheumatol-
ogy (22), to be positive for rheumatoid factor (RF) and/or
anti–cyclic citrullinated peptide (anti-CCP) antibodies, and to
have a disease duration of 6 months and a Disease Activity
Score in 28 joints (DAS28) of 4.0 (23). The PsA patients
were required to have psoriasis at screening, 3 swollen and
3 tender peripheral joints, negativity for RF and anti-CCP
antibodies, and a disease duration of 6 months. Treatment
with at least 1 disease-modifying antirheumatic drug
(DMARD) had failed for all patients, and all patients were
treated with methotrexate at a dose of at least 7.5 mg weekly,
stable for at least 4 weeks prior to commencing anti-TNF
therapy. No other DMARDs were allowed within the 4 weeks
prior to commencing treatment, but prednisolone was allowed
provided the dose remained stable and did not exceed 10 mg
daily.
Participants (16 RA patients and 20 PsA patients) were
randomly assigned to receive 3 mg/kg infliximab at weeks 0, 2,
and 6 and then every 8 weeks until week 46, or to receive 25 mg
etanercept twice weekly for 52 weeks. Therapy was kept stable
for the first 3 months. After 3 months, therapy could be changed
as required, including escalation of methotrexate therapy to
25 mg weekly in apparent nonresponders. Clinical data, includ-
ing erythrocyte sedimentation rate, DAS28, and Health As-
sessment Questionnaire scores (24), were collected at baseline
and monthly up to week 52. A good clinical response in RA
was defined as a DAS28 of 3.2 and improvement in the
DAS28 of1.2 after therapy (25). A good response in PsA was
defined as an improvement in 2 factors (with at least 1 being a
joint count) with worsening in none of the following 4 factors:
patient’s global assessment of disease activity, physician’s
global assessment of disease activity, tender joint count, and
swollen joint count (26). Random urine samples were collected
from the patients at baseline and at 12 weeks and were
snap-frozen and stored at –80°C. The study was conducted in
compliance with the Declaration of Helsinki, and ethical
approval was obtained from the West Glasgow Ethics Com-
mittee. All subjects gave written informed consent.
Metabolomic analysis. After thawing, urine samples
(1 ml) were centrifuged at 13,000g for 5 minutes, and samples
were prepared using a standard protocol (27). Briefly, urine
was buffered with phosphate buffer (100 mM), brought to
concentrations of 10% D2O and 0.5 mM TMSP, and the pH
was adjusted to 7.0 twice over 30 minutes. The sample was then
centrifuged and loaded into a standard 5-mm NMR tube for
spectroscopy.
One-dimensional (1-D) 1H spectra were acquired at
300°K using a standard spin-echo pulse sequence with water
suppression using excitation sculpting on a Bruker DRX 500
MHz NMR spectrometer equipped with a cryoprobe. Samples
were processed and data were calibrated with respect to the
TMSP signal. Spectra were read into Prometab (28) (custom
written software in MatLab 7; MathWorks) and were trun-
cated to a range of 0.8–10.0 parts per million. Spectra were
segmented into 0.005 ppm (2.5 Hz) chemical shift “bins,” and
the spectral areas within each bin were integrated. Spectra
were corrected for baseline offset and then normalized to a
total spectral area of unity, and a generalized log transforma-
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tion was applied (28). Binned data were then compiled into a
matrix, with each row representing an individual sample.
Measurement of metabolites. Glutamine levels were
measured in the urine samples using high-performance ion-
exchange chromatography. Xanthurenic acid levels were mea-
sured using a fluorometric method (29).
Statistical analysis. The data bins from groups of
spectra were mean-centered and then assessed using 3 tech-
niques. First, partial least-squares discriminant analysis (PLS-
DA) was used to perform supervised clustering of samples
using PLS_Toolbox (version 5.8; Eigenvector Research) in
MatLab (release 2009a). PLS-DA was cross-validated using
Venetian blinds (30), a method that reassigns randomly se-
lected blocks of data to the PLS-DA model to determine the
accuracy of the model in correctly assigning class membership.
Second, GALGO, a package available in the statistical envi-
ronment R, was used to further model the relationship be-
tween good responders and those who did not respond well
using a genetic algorithm search procedure coupled to statis-
tical modeling methods for supervised classification (31). The
results of GALGO analyses are presented as principal compo-
nents analysis (PCA) plots, where the x- and y-axes represent
first and second principal components providing the greatest
variation between samples and the next largest unrelated
variation, respectively. GALGO analysis was cross-validated
using K-fold cross-validation, where the original sample is
randomly partitioned into subsamples and each observation is
used for both training and validation. Finally, we used partial
least-squares regression, a regression method that identifies
which metabolites can predict a continuous variable. This
analysis yields r2, a measure of the goodness-of-fit of the linear
regression, while permutation testing assessed the significance
of this prediction.
Lists of metabolites providing the greatest discrimina-
tion between groups were then identified for each technique.
Using multivariate analyses, peaks with large weightings were
identified from the PLS-DA weightings plot. Metabolites were
identified using these peaks. GALGO analysis produces a list
of “bins” of ranked importance which contribute to the
separation between the groups. The partial least-squares re-
gression model represents the 90 “bins” or regions of the
spectra which had the greatest influence on the correlation
with the change in DAS28. These bins were used to identify the
discriminatory metabolites. An NMR database (Human
Metabolome Database version 2.5) and Chenomx NMR suite
were used to identify the metabolites.
RESULTS
Prediction of response to anti-TNF therapy. Af-
ter 12 months of anti-TNF therapy, RA patients were
divided into 2 groups according to their response, as
determined by EULAR criteria (Table 1). Response to
anti-TNF therapy was also assessed at 3 months, but only
4 patients had a good response (as determined by
EULAR criteria) at this stage. Only 1 PsA patient did
not respond to treatment with a TNF antagonist accord-
ing to the predefined response criteria; it was therefore
not possible to look at prediction of response in PsA.
NMR spectra of stored baseline urine samples
were acquired and analyzed in order to identify differ-
ences between the 2 groups. Supervised PLS-DA analy-
sis (Figure 1A) showed a clear distinction between
patient groups segregated according to clinical response.
This model distinguished samples with or without a good
response with a sensitivity of 66.7% and a specificity of
57.1%. A weightings plot, which indicates regions of the
NMR spectra that contribute to this separation (Figure
1B), was used to identify the discriminatory metabolites
responsible for the difference in response, and these are
shown in Table 2.
The partial least-squares regression model repre-
sents the 90 “bins” or regions of the spectra that had the
greatest influence on the correlation with the change in
DAS28. The GALGO model identifies the bins that
have the greatest influence on the separation. For the
PLS-DA model, the metabolites were identified from
the weightings plot, which indicates regions of the NMR
spectra that contribute to the separation. The top 20 bins
were identified using GALGO and partial least-squares
regression and the metabolites identified from these 20
bins. From the PLS-DA weightings plot the top 20 peaks
Table 1. Baseline characteristics of rheumatoid arthritis patients, by
response to anti-TNF therapy at 12 months*
Good response
to TNF
antagonists
(n  7)
Not good response
to TNF
antagonists
(n  9)†
Age, years 50.0  13.40 52.67 12.83
Female, no. (%) 7 (100) 9 (100)
BMI, kg/m2 26.16  3.75 26.97 5.64
Prednisolone, no. receiving 1 2
NSAIDs, no. receiving 4 4
Baseline methotrexate dose,
mg/week
13.57  4.76 15.83 6.12
DAS28 6.041 1.06 6.46 0.91
CRP, mg/ml 21.31 15.97 7.02 7.97
RF positive, no. 6 8
Anti-CCP antibody positive, no. 6 8
Urinary albumin-to-creatinine
ratio
1.60  2.71 0.29 0.45
* Except where indicated otherwise, values are the mean SD. Except
for the C-reactive protein (CRP) level (P  0.03 by unpaired t-test),
there were no significant differences between the groups. Anti-TNF 
anti–tumor necrosis factor; BMI  body mass index; NSAIDs 
nonsteroidal antiinflammatory drugs; DAS28Disease Activity Score
in 28 joints; RF  rheumatoid factor; anti-CCP  anti–cyclic citrulli-
nated peptide.
† Corresponds to moderate and poor response, as determined by
European League Against Rheumatism criteria.
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were identified, and the metabolites were identified
from these.
GALGO analysis was then used to reanalyze the
data, first in order to verify the results obtained using a
Figure 1. Metabolic fingerprinting distinguishes between baseline urine samples from rheumatoid arthritis (RA) patients who have good responses
to tumor necrosis factor (TNF) antagonists at 12 months and those who do not. A, One-dimensional 1H nuclear magnetic resonance (NMR) spectra
of baseline urine samples from RA patients with (solid circles) or without (open circles) a good response to TNF antagonists at 12 months were
subjected to supervised analysis (partial least-squares discriminant analysis [PLS-DA]). The sample number is plotted against the score in
(contribution to) latent variable 1 (LV1), and the percent value on the y-axis shows the proportion of the total variance in the data captured by LV1
in the PLS-DA model. The horizontal dashed line at zero segregates samples with positive and negative scores. B, Weightings plot of the PLS-DA
model of spectral data from baseline urine samples from the RA patients who did or did not have a good response at 12 months highlights major
regions of the spectra that distinguish between the sample groups. The major discriminating peaks are labeled with their chemical shift (in parts per
million) on the x-axis and LV weighting on the y-axis. The percent value on the y-axis indicates the proportion of the total variance in the data
captured by LV1. C, One-dimensional 1H NMR spectra of baseline urine samples from RA patients with (solid circles) or without (open circles)
a good response to TNF antagonists at 12 months were subjected to principal components analysis using GALGO analysis. The percent values on
the x and y axes indicate the proportion of the variance captured by each principal component (PC1 and PC2).
Table 2. Baseline urinary metabolites most strongly correlated with response to anti-TNF therapy using partial least-squares regression, GALGO,
and PLS-DA models*
Rank†
Metabolite (chemical shift[s],
in ppm), PLS-DA model‡
VIP
value§
Metabolite (chemical shift[s],
in ppm), GALGO model
Metabolite (chemical shift[s],
in ppm), partial least-squares
regression model
1 1Histamine (7.15)¶ 91.54 Trimethylamine (2.87) Citrate (2.67, 2.53, 2.56)
2 1Glutamine (2.16, 2.34)¶ 87.72 Thiamine (7.41) Phosphocreatinine (3.04, 3.94)#
3 2p-hydroxyphenylpyruvic acid
(4.06, 7.14, 6.82, 7.12)#
72.72 Histamine (7.24, 8.01, 8.00, 7.12)¶ Ethanolamine (3.16, 3.74)¶
4 2Phosphocreatine (3.05, 3.94)# 60.58 Thymine (7.37, 7.35, 1.86)# Creatinine (4.05, 4.06, 3.05)#
5 1Thymine (7.35, 1.86)# 61.8 Ethanolamine (3.17, 3.80)¶ Histamine (7.13, 3.28, 7.15)¶
6 1Creatinine (3.04, 4.05)# 50.58 Phenylacetic acid (7.29, 7.39, 7.30)# Glutamine (2.16)¶
7 1Xanthurenic acid (7.37, 7.13)¶ 36.71 Glutamine (2.12, 2.13)¶ p-hydroxyphenylpyruvic acid (6.82,
6.8225, 4.06, 7.12)#
8 1Phenylacetic acid
(3.63, 7.44, 7.32)#
21.48 Xanthurenic acid (6.96)¶ Dimethylamine (2.70)
9 1Xanthine (7.82)# 12.68 Xanthine (7.90)# Xanthurenic acid (7.15)¶
10 2Ethanolamine (3.80)¶ 7.59 Tartaric acid (4.38) –
11 – – 3-phosphoglyceric acid (4.14) –
* The top 20 bins (partial least-squares regression and GALGO models) and peaks (partial least-squares discriminant analysis [PLS-DA] model)
were identified; the metabolites these represent and their corresponding chemical shifts in parts per million are shown.
† Extent of contribution to differentiation between responders and nonresponders to anti–tumor necrosis factor (anti-TNF) agents.
‡1 indicates up-regulation of metabolites in urine samples from patients who had a good response to TNF antagonists.2 indicates down-regulation
of metabolites in urine samples from patients who had a good response to TNF antagonists.
§ Variable importance of the projection (VIP) values were calculated using PLS-DA.
¶ Identified by all 3 methods.
# Identified by 2 different methods.
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further supervised analysis technique, and second to use
the superior modeling power of the GALGO genetic
algorithm, which removes irrelevant variables more ef-
fectively. The PCA plot yielded by GALGO analysis
showed a clear distinction between RA patients segre-
gated according to clinical response (Figure 1C). The
cross-validation of this model was shown to distinguish
samples from patients who would not have a good
response and samples from patients who would have a
good response with a greatly improved sensitivity of
88.9% and specificity of 85.7%. GALGO analysis was
further used to identify the discriminatory metabolites
responsible for the difference in response as shown in
Table 2.
Finally, the relationship between baseline metab-
olite profiles and the change in DAS28 over 12 months
was assessed using partial least-squares regression. This
analysis was repeated 100 times with and without ran-
domization of the NMR bin data. There was a significant
association between the change in DAS28 and baseline
RA metabolites (P  0.04). Permutation testing with 90
NMR bins included (as optimized by forward selection)
demonstrated that the regression model was statistically
valid (P  0.01).
There was a significant difference between the
C-reactive protein (CRP) level of patients who re-
sponded to TNF antagonists and the CRP level of those
who did not respond (P  0.03). We therefore used
partial least-squares regression to further analyze the
relationship between CRP and baseline metabolites in
order to investigate potential confounding variables; this
did not reveal any significant association (P  0.52),
suggesting that the difference we found was independent
of the inflammatory processes reflected in the CRP
levels. Grouping the metabolite data into quartiles ac-
cording to the CRP values also failed to separate patient
groups on PCA or PLS-DA (data not shown). Previous
studies have shown that patients with RA have subclin-
ical nephropathy (32,33) and that the urinary albumin-
to-creatinine ratio is a sensitive marker of disease activ-
ity in RA (32). We measured the albumin-to-creatinine
ratio in the urine samples, and there was no significant
difference in this ratio between patients who responded
to TNF antagonists and those who did not (P  0.17).
We also performed regression analysis for metabolic
profiles at baseline against the albumin-to-creatinine
ratio, and this was not significant (P  0.31), suggesting
that the relationship we found between baseline urinary
metabolic profiles and the DAS28 was independent of
microalbuminuria.
Comparison of metabolites predicting response
to therapy in RA. Metabolites that were associated with
a change in the DAS28 are shown in Table 2. The
metabolites histamine, glutamine, xanthurenic acid, and
ethanolamine were identified by all 3 analytic methods.
Furthermore, several metabolites were identified by at
least 2 of the 3 different methods, including p-
hydroxyphenylpyruvic acid, phosphocreatine, thymine,
creatinine, phenylacetic acid, and xanthine. These find-
ings cross-validate the analyses used. We were also able
to identify glutamine and xanthurenic acid in the urine
samples that were used for NMR analysis using ion-
exchange chromatography and a fluorometric method,
respectively. There was a good correlation between the
NMR peak heights and the assayed levels of xanthurenic
acid (r  0.73 [Spearman’s correlation coefficient], P 
0.001) and a strong trend in the results for glutamine
(r 0.46 [Spearman’s correlation coefficient], P 0.07),
which helped to validate our interpretation of the NMR
data. However, the assayed levels of glutamine and
xanthurenic acid were not significantly higher in the
urine samples from the patients who had a good re-
sponse, which suggests that while these individual me-
tabolites contribute strongly to the discrimination, the
whole set of metabolites present in the fingerprints is
needed to fully separate the groups.
Effect of TNF antagonists on metabolite pro-
files. The details of the patients receiving etanercept and
infliximab are shown in Table 3. We investigated the
effect of anti-TNF therapy on metabolic profiles longi-
tudinally, comparing baseline and 12-week (during ther-
apy) urine samples using supervised PLS-DA analysis
(sensitivity of 71.4% and specificity of 57.1% in RA and
sensitivity and specificity of 61.1% in PsA) and GALGO
analysis (sensitivity of 100% and specificity of 82.9% in
RA and sensitivity of 71.8% and specificity of 69.5% in
Table 3. Characteristics of the rheumatoid arthritis and psoriatic
arthritis patients, by treatment group*
Patients receiving
infliximab
(n  18)
Patients receiving
etanercept
(n  16)
Age, years 48.6 10.60 47.46  14.78
Female, no. (%) 13 (72) 13 (81)
BMI, kg/m2 28.43  4.56 28.36  9.33
Prednisolone, no. receiving 6 3
NSAIDs, no. receiving 10 9
DAS28 at baseline† 6.22  0.95 6.35  1.05
* Except where indicated otherwise, values are the mean  SD. See
Table 1 for definitions.
† Rheumatoid arthritis patients only.
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Figure 2. Metabolic fingerprinting enables identification of metabolites that are altered after treatment with TNF antagonists in patients with a
good response. A, One-dimensional 1H NMR spectra of urine samples obtained at baseline (open circles) and 12 weeks (solid circles) from RA
patients with a good response to TNF antagonists at 12 months were subjected to supervised analysis (PLS-DA). The score in LV1 is plotted against
the score in LV2, and the percent values on the x and y axes show the proportions of the total variance in the data captured by LV1 and LV2 in
the PLS-DA model. The horizontal dashed lines at zero segregate samples with positive and negative scores. B, Weightings plot of the PLS-DA
model of spectral data from urine samples obtained from RA patients who responded to TNF antagonists highlights major regions of the spectra
that distinguish between the baseline and 12-week samples. The major discriminating peaks are labeled with their chemical shift (in parts per million)
on the x-axis and LV weighting on the y-axis. The percent value on the y-axis indicates the proportion of the total variance in the data captured by
LV1. C, One-dimensional 1H NMR spectra of urine samples obtained at baseline (open circles) and 12 weeks (solid circles) from psoriatic arthritis
(PsA) patients with a good response to TNF antagonists at 12 months were subjected to supervised analysis (PLS-DA). The score in LV1 is plotted
against the score in LV2, and the percent values on the x and y axes show the proportions of the total variance in the data captured by LV1 and
LV2 in the PLS-DA model. The horizontal dashed lines at zero segregate samples with positive and negative scores. D, Weightings plot of the
PLS-DA model of spectral data from urine samples from PsA patients who responded to TNF antagonists highlights major regions of the spectra
that distinguish between the baseline and 12-week samples. The major discriminating peaks are labeled with their chemical shift (in parts per million)
on the x-axis and LV weighting on the y-axis. The percent value on the y-axis indicates the proportion of the total variance in the data captured by
LV1. See Figure 1 for other definitions.
Figure 3. Metabolic fingerprinting of urine samples from RA patients and psoriatic arthritis (PsA) patients. A, One-dimensional 1H NMR spectra
of urine samples obtained 12 weeks after treatment with infliximab (open circles) or etanercept (solid circles) from RA and PsA patients with a good
response to treatment were subjected to supervised analysis (PLS-DA). The score in LV1 is plotted against the score in LV2, and the percent values
on the x and y axes show the proportions of the total variance in the data captured by LV1 and LV2 in the PLS-DA model. The horizontal dashed
lines at zero segregate samples with positive and negative scores. B, Weightings plot of the PLS-DA model of spectral data from urine samples
obtained after treatment with infliximab or etanercept from RA and PsA patients with a good response at 12 months highlights major regions of
the spectra that distinguish between the sample groups. The major discriminating peaks are labeled with their chemical shift (in parts per million)
on the x-axis and LV weighting on the y-axis. The percent value on the y-axis indicates the proportion of the total variance in the data captured by
LV1. See Figure 1 for other definitions.
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PsA). Using the weightings plot, we determined that in
patients with RA who responded to TNF antagonists
there were high levels of glutamine, phenylacetic acid,
and histamine in the baseline urine samples and higher
levels of methylamine and creatinine in the 12-week
urine samples. Similar changes in metabolites were also
seen in the urine samples from the patients with PsA
who responded to TNF antagonists (Figure 2).
Combining RA and PsA patients with a good
response, we assessed which urinary metabolites
changed after 12 weeks of treatment with infliximab and
with etanercept using supervised PLS-DA analysis (sen-
sitivity of 84.6% and specificity of 55.6%) (Figure 3) and
GALGO analysis (sensitivity of 86.2% and specificity of
100%). Using the weightings plot, we found that in-
creases in hippuric acid, citrate, and lactic acid were seen
with infliximab treatment and increases in choline, phe-
nylacetic acid, urea, creatine, and methylamine were
seen with etanercept treatment. Due to the small patient
numbers, we could not investigate the effects of etaner-
cept and infliximab in RA and PsA separately.
DISCUSSION
There were clear differences in the metabolic
profiles of baseline urine samples of patients with RA
who responded well to anti-TNF therapy compared with
those who did not. This difference may be important as
a novel predictor of responses to TNF antagonists. We
have used 3 different data analysis methods to predict
response, and each found that similar metabolites con-
tributed. We have used GALGO analysis as well as
PLS-DA analysis as it has been shown that genetic
algorithms optimize the results by removing irrelevant
variables, which dramatically improves the classification
ability of models (34). All 3 methods identified hista-
mine, glutamine, xanthurenic acid, and ethanolamine,
while both PLS-DA and partial least-squares regression
identified creatinine, p-hydroxyphenylpyruvic acid, and
phosphocreatine, and both PLS-DA and GALGO iden-
tified phenylacetic acid and xanthine. Histamine, glu-
tamine, phenylacetic acid, xanthine, xanthurenic acid,
and creatinine were up-regulated in the urine samples
from the patients who had a good response to therapy,
while ethanolamine, p-hydroxyphenylpyruvic acid, and
phosphocreatine were down-regulated.
One metabolite we identified as a strong discrim-
inator in baseline urinary metabolites was histamine.
Urinary histamine metabolites have also been suggested
as a marker of disease activity in IBD (35), suggesting
that it may be a generic marker of inflammatory pro-
cesses. Histamine is most obviously associated with mast
cell–dependent processes such as allergy, and histamine
has been identified as a constituent of synovial fluid in
arthritis (36). Histologic examination of synovial infil-
trates in early RA has shown mast cells to be present
(37), suggesting that these cells could be the source of
the discriminating histamine. However, an alternative
but significant route for histamine generation is via
histidine degradation. Histamine arises in many tissues
by the decarboxylation of histidine (38). It has long been
known that TNF promotes cachexia associated with
chronic inflammatory disease, and this cytokine is
known to have direct effects in accelerating muscle
breakdown, leading to the release of free amino acids
including histidine (39). Consistent with this, levels of
histidine have been shown to be considerably higher in
patients with RA and patients with systemic lupus
erythematosus (40) compared to levels in controls.
Several of the other metabolites that we observed
were also associated with catabolic processes and tissue
degradation; for example, glutamine, xanthurenic acid,
and ethanolamine can result from tryptophan and other
amino acid degradation pathways. Tryptophan has been
shown to be down-regulated in the plasma of patients
with ankylosing spondylitis (AS) compared with the
plasma of controls (41). The release of tryptophan from
its binding serum protein has been shown to correlate
with improvement in disease activity in AS (41), and this
may be the same in RA.
A previous metabolomic study has suggested that
alterations in serum levels of amino acids may be a
useful marker of the presence and severity of osteoar-
thritis in the knee (42). The urine markers that we found
either may be indicators of joint-specific degradation
processes or may result from the systemic muscle and
tissue changes associated with chronic disease, many of
which are mediated through TNF.
Previous work has investigated predictors of re-
sponse to TNF antagonists. Analysis of patients in the
British Society for Rheumatology Biologics Register
found that treatment with methotrexate or nonsteroidal
antiinflammatory drugs (NSAIDs) predicted response to
TNF antagonists (43). All the patients in our study were
receiving methotrexate, and there were an equal number
of patients receiving NSAIDs who had a good response
compared to those who did not. Smoking has been
associated with a poor response to infliximab (43), but
only 1 of our patients smoked. Another group has found
that the presence of RF or anti-CCP antibodies is
associated with a reduced response to TNF antagonists
(44), but all of our RA patients were positive for RF
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and/or anti-CCP antibodies. Baseline levels of TNF
may predict the dose of infliximab needed for optimal
response (45), and other work has demonstrated that a
combination of blood cytokines and autoantibodies can
predict responses to etanercept (46). In our cohort there
was a significant difference between CRP levels in
patients who responded to TNF antagonists and those
who did not. However, the partial least-squares regres-
sion analysis failed to find an association between CRP
and baseline metabolites, suggesting that the association
between baseline metabolites and response is indepen-
dent of CRP.
Infliximab and etanercept alter metabolites in the
urine differently, as there are clear differences in the
metabolites at 12 weeks posttreatment. Increases in the
metabolites hippuric acid, citrate, and lactic acid were
associated with infliximab treatment, and increases in
the metabolites choline, phenylacetic acid, urea, crea-
tine, and methylamine were associated with etanercept
treatment. The presence of choline suggests that etan-
ercept may alter lipid metabolism.
We have also shown that the same metabolites
are altered in the urine samples from patients with RA
and PsA who responded to TNF antagonists. It may
therefore be that chronic inflammatory diseases respond
by a common mechanism to TNF antagonists.
This is the first demonstration that metabolomic
techniques using 1-D NMR spectra can predict outcome
to anti-TNF therapy in patients with severe RA, provid-
ing a sensitivity and specificity for response that has
potential clinical utility despite a small initial cohort of
patients. Our findings are verified by repeat analysis
using alternative statistical techniques. There is a press-
ing need to confirm and extend these findings in a larger
cohort of patients, combining metabolomic analyses with
CRP and cytokine and autoantibody analyses to develop
tests that can predict response without the need for
empirical treatment, bringing closer the era of individu-
ally tailored therapy.
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